Novartis is aiming to distinguish new psoriasis med Cosentyx from the rest of the next-gen field by building up its label, adding nods for conditions including ankylosing spondylitis. But it'll have some competition in that space, too.
Social media success in consumer marketing has advanced beyond counting fans and followers. Today it's all about shares, retweets and links that indicate real consumer engagement with brands....
For the second quarter of the year, Johnson & Johnson as usual has the pole position on reporting, and CEO Alex Gorsky was on hand with a midyear update.
Although the waning Ebola outbreak had Big Pharmas struggling to find volunteers for their Ebola vaccine trials, two new Phase II trials are going forward. GlaxoSmithKline will take its candidate to Senegal, while Johnson & Johnson and partner Bavarian Nordic will test their vaccine in France and the U.K.
Two Johnson & Johnson consumer health plants that operate under a consent decree from the FDA will no longer need to be monitored by outsiders, and the plant that was ground zero for the company's consumer health quagmire is expected to go back online after being sidelined for 5 years to regain standing with the FDA.
Johnson & Johnson knows that "competition in the immunology space is fierce," as CEO Alex Gorsky admitted on the company's second-quarter conference call. After all, companies developing next-gen psoriasis-fighters have recently been going head-to-head against the company's Stelara to prove their efficacy. But the New Jersey pharma giant isn't planning on being left behind.
The search for an HIV vaccine has been long and difficult, but researchers from Johnson & Johnson, Harvard and other groups may have made a leap. J&J's Janssen reported encouraging results Thursday from its preclinical trial of an HIV vaccine in rhesus monkeys. Encouraging enough for the company to sponsor human studies--the first time a Big Pharma is doing so in the HIV space.
Price checks by India's National Pharmaceutical Pricing Authority on certain orthopedic implants have once again raised hackles by companies concerned they are being swept up in a law that was not meant for their industry, Business Standard reports.
Multinational drug firms in Australia faced a string of barbs in hearings held by a Senate panel into transfer pricing that included a reference to a fictitious German World War II prison camp guard.
For a while now, Bayer and Johnson & Johnson's Xarelto has had no problem besting its competition, zooming to the lead in the new-age anticoagulant market, despite entering second. Now, though, the notion that rival Eliquis is a superior med is permeating the field, and it's up to the companies to quash that idea if they want to keep their hold on the No. 1 spot.